Home > Oncology > CheckMate 9ER offers RCC new frontline option; perspectives from the study’s principle investigator

CheckMate 9ER offers RCC new frontline option; perspectives from the study’s principle investigator

Principal Investigator
Prof. Toni Choueiri, Dana Farber Cancer Institute, Harvard University, Boston, USA
Conference
ESMO Virtual Congress 2020
Trial
Phase 3, CheckMate 9ER
Prof. Toni Choueiri (Dana Farber Cancer Institute, Harvard University, Boston, USA) presented the late-breaking results of the phase III CheckMate 9ER trial evaluating the combination of nivolumab and cabozantinib compared to sunitinib in untreated patients with advanced or metastatic renal cell carcinoma (RCC) at the ESMO Virtual Congress 2020 held 19-21 September, 2020 [1]. All endpoints were met, making this combination the newest frontline therapy option likely to be added to guidelines. Prof. Choueri discussed the implications with our journalist. Efficacy results Each of these treatments has proven survival benefit as single agents for metastatic RCC. CheckMate 9ER i...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on